Lipomics Technologies to Partner with UC Davis

Lipomics will retain certain rights to develop diagnostic applications based on the data from the studies. Lipomics seeks to partner with academic institutions and drug companies to advance its goal of developing diagnostic tests for metabolic diseases.
"This is a valuable collaboration as we pursue discovery of markers for health and disease. Understanding individual response is essential to understanding metabolic disease and approaches to therapy and preventative care. We look forward to working with one of the nation's premier research institutions,” said Steve Watkins, president and chief scientific officer at Lipomics.

Lipomics Technologies provides industry-leading metabolic assessments for clinical diagnostics, personalized medicine, and drug research. The company's proprietary analytic technologies generate comprehensive, accurate, and quantitative profiles of lipid metabolites. A broad range of bioinformatics and analytic tools map these profiles to the underlying biochemical pathways. Through these tools, Lipomics delivers deep and rich knowledge about biological and metabolic changes induced by disease, drug action, nutritional, or lifestyle influences.

In partnership with pharmaceutic, biotechnology, and nutrition companies, Lipomics uses its technologies to discover new diagnostic biomarkers, improve drug discovery, develop companion diagnostics, and enable individualized health management.


Related Links:
Lipomics
University of California, Davis